GIP/GLP-1 & amylin agonists × body weight & composition

TrialThe New England journal of medicine2022

Tirzepatide Once Weekly for the Treatment of Obesity.

Ania M Jastreboff et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 2,539 people · 2022

Randomised comparison

Lowered body weight & composition

−15.0percentage points−15.9 to −14.2

As reported

difference −15.0 %, 95% CI −15.9 to −14.2

Randomised comparison

Lowered body weight & composition

−85.0percentage points−89.0 to −82.0

As reported

difference −85.0 %, 95% CI −89.0 to −82.0

Randomised comparison

Lowered body weight & composition

−3.00percentage points−5.00 to −1.00

As reported

difference −3.00 %, 95% CI −5.00 to −1.00

Three numbers in the abstract

the abstract, start to end

change in weight at week 72 was -15.0% (95% confidence interval [CI],

had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the

← favours treatmentfavours comparator →
could be chance
Body weight & composition
−15.0−15.9 to −14.2
Body weight & composition
−85.0−89.0 to −82.0
Body weight & composition
−3.00−5.00 to −1.00
GIP/GLP-1 & amylin agonistsBody weight & composition

GIP/GLP-1 & amylin agonists × body weight & compositionhelps?replicated

unlikelylikely
1.001.00 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

1,647 papers cite itlatest 60 shown

2022
2026
this paperpooled ittrialcites it

10 trials

Full record →Abstract, authors, funding and every citing paper · PMID 35658024